July 23, 2014 10:57 AM ET

Capital Markets

Company Overview of Research Corporation Technologies Inc.

Company Overview

Research Corporation Technologies Inc. is a venture capital firm specializing in incubations, start up, and early-stage companies. It is a technology development company that typically invests in new technology platforms in life sciences, biomedical, preclinical and clinical-stage therapeutics, devices, drugs, and diagnostics, and biotech tools for gene expression and protein production. Within preclinical and clinical-stage drugs, diagnostics and devices, the firm focuses on cancer, pain and metabolic diseases; cardiovascular diseases; back-of-the-eye and immune disorders; and infectious diseases and diagnostics. Within cancer, the firm focuses on anticancer agents, agents to treat cancer-...

5210 East Williams Circle

Suite 240

Tucson, AZ 85711-4410

United States

Founded in 1987

Phone:

520-748-4400

Fax:

520-748-0025

Key Executives for Research Corporation Technologies Inc.

President of Biotechnologies and Director
President of Medical Devices
Managing Director
Director of Administration
Compensation as of Fiscal Year 2014.

Research Corporation Technologies Inc. Key Developments

Research Corporation Technologies and BioGrammatics Announce their Partnership to Commercialize and Distribute Pichia GlycoSwitch

Research Corporation Technologies and BioGrammatics Inc. announced their partnership to commercialize and distribute Pichia GlycoSwitch (R) -- a new expression system to modify the glycosylation of recombinant proteins in the yeast Pichia pastoris. Pichia GlycoSwitch(R) adds to the advantages of using Pichia pastoris as a host for the production of recombinant proteins with increased flexibility over protein glycosylation (the addition of sugars to a protein of interest). Under the partnership, BioGrammatics will provide expression system kits and services; RCT will oversee commercial licensing programs.

Lucigen Corporation and Research Corporation Technologies Announce Partnership and Launch Endotoxin-free CleanColi™ Expression System

Lucigen Corporation and Research Corporation Technologies (RCT) announced a partnership to commercialize and distribute the CleanColi™ Expression System, the first Escherichia coli (E. coli)-based recombinant system that lacks unwanted endotoxin. Lucigen will produce and sell kits containing CleanColi™ competent cells and provide contract research services for the CleanColi™ Expression System. Lucigen simultaneously announces the release of a CleanColi™ competent cell line enabling the production of proteins virtually free of endotoxin contamination, thereby minimizing purification and allowing faster and more accurate screening of biological targets for drug discovery research. Under the partnership, RCT will be responsible for the CleanColi™ commercial licensing programs. Drug discovery researchers are increasingly turning to biologics as the source for new therapeutics, utilizing the incredible diversity of proteins in order to find new treatments for disease. To synthesize and manipulate these proteins, researchers normally insert genes coding for the desired protein into mammalian, yeast, or bacterial cells. The common bacteria E. coli is a widely used system for expression of recombinant proteins, but this method has the disadvantage that, without time-consuming and expensive cleanup, it produces contaminating endotoxin that kills human cells. Failure to remove endotoxin from the final product can result in false or misleading results, potentially causing a researcher to improperly reject a promising drug candidate. Lucigen and RCT have developed the CleanColi™ competent cell strain for protein expression. This new strain has a genetically modified lipopolysaccharide (LPS) that does not cause an endotoxic response in human cells. By producing proteins without contaminating endotoxin, researchers can increase productivity by reducing the time, cost, and loss of product associated with endotoxin removal. More important, cell-based assays can be performed without concern that LPS (endotoxin) contamination could be masking promising results. Researchers can accelerate drug discovery research and ensure the most accurate results possible. Additional cell lines for plasmid production and phage display are also planned for release, creating a complete system for scientists to study a large variety of biologic compounds for therapeutic applications.

Research Corporation Technologies Inc. Presents at EBD Group AG's Biotech showcase 2013, Jan-07-2013

Research Corporation Technologies Inc. Presents at EBD Group AG's Biotech showcase 2013, Jan-07-2013 . Venue: Parc 55 Wyndham Union Square Hotel, San Francisco, California, United States.

Similar Private Companies By Industry

Company Name Region
R.V. Kuhns & Associates, Inc. United States
KCI Investing United States
China Holdings Group, Inc. United States
AltQuest Group United States
Colorow Partners, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
April 17, 2014
E.I. Spectra, LLC
Merger/Acquisition
October 15, 2013
ADC Products Ltd.
Private Placement
October 8, 2013
Providence Medical Technology, Inc.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Research Corporation Technologies Inc., please visit www.rctech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.